Yanjun Xu

Publication Activity (10 Years)

Years Active: 2022-2024
Publications (10 Years): 13

Top Topics

Advanced Non Small Cell Lung Cancer

Ejection Fraction

Top Venues

Cell death & disease

Molecular cancer therapeutics

Therapeutic advances in medical oncology

Journal of translational medicine

This page only lists publications with an associated author ORCID identifier.

Publications

Kaibo Ding, Zhongsheng Peng, Dujiang Liu, Yanjun Xu
Sunvozertinib overcoming resistance to afatinib and osimertinib in lung adenocarcinoma harboring an EGFR exon 18 DelE709_T710insD mutation. Journal of translational medicine 22 (1) (2024)
Yanjun Xu, Kaibo Ding, Zhongsheng Peng, Ling Ding, Hui Li, Yun Fan
Evaluating for correlations between metabolites in patients receiving immunotherapy for metastatic or recurrent NSCLC: an exploratory study based on two cohorts. Molecular cancer therapeutics (2024)
Yanjun Xu, Kaibo Ding, Zhongsheng Peng, Ling Ding, Hui Li, Yun Fan
Evaluating for Correlations between Specific Metabolites in Patients Receiving First-Line or Second-Line Immunotherapy for Metastatic or Recurrent NSCLC: An Exploratory Study Based on Two Cohorts. Molecular cancer therapeutics 23 (5) (2024)
Yanjun Xu, Kaibo Ding, Zhongsheng Peng, Ling Ding, Hui Li, Yun Fan
Evaluating for Correlations between Specific Metabolites in Patients Receiving First-Line or Second-Line Immunotherapy for Metastatic or Recurrent NSCLC: An Exploratory Study Based on Two Cohorts. Molecular cancer therapeutics 23 (5) (2024)
Kaibo Ding, Zhongsheng Peng, Yanjun Xu
Role of immunotherapy in pulmonary sarcomatoid carcinoma: review of current approaches and related biomarkers. Therapeutic advances in medical oncology 16 (2024)
Kaibo Ding, Zhongsheng Peng, Yanjun Xu
Role of immunotherapy in pulmonary sarcomatoid carcinoma: review of current approaches and related biomarkers. Therapeutic advances in medical oncology 16 (2024)
Yanjun Xu, Kaibo Ding, Zhongsheng Peng, Ling Ding, Hui Li, Yun Fan
Evaluating for Correlations between Specific Metabolites in Patients Receiving First-Line or Second-Line Immunotherapy for Metastatic or Recurrent NSCLC: An Exploratory Study Based on Two Cohorts. Molecular cancer therapeutics 23 (5) (2024)
Kaibo Ding, Zhongsheng Peng, Dujiang Liu, Yanjun Xu
Sunvozertinib overcoming resistance to afatinib and osimertinib in lung adenocarcinoma harboring an EGFR exon 18 DelE709_T710insD mutation. Journal of translational medicine 22 (1) (2024)
Hui Li, Yong-Chang Zhang, Yanjun Xu, Zhiyu Huang, Guoping Cheng, Ming-Ying Xie, Zi-Chao Zhou, Yangyang Yu, Wenjing Xi, Yun Fan
Tumor immune microenvironment and immunotherapy efficacy in BRAF mutation non-small-cell lung cancer. Cell death & disease 13 (12) (2022)
Hui Li, Yong-Chang Zhang, Yanjun Xu, Zhiyu Huang, Guoping Cheng, Ming-Ying Xie, Zi-Chao Zhou, Yangyang Yu, Wenjing Xi, Yun Fan
Tumor immune microenvironment and immunotherapy efficacy in BRAF mutation non-small-cell lung cancer. Cell death & disease 13 (12) (2022)
Hui Li, Yong-Chang Zhang, Yanjun Xu, Zhiyu Huang, Guoping Cheng, Ming-Ying Xie, Zi-Chao Zhou, Yangyang Yu, Wenjing Xi, Yun Fan
Tumor immune microenvironment and immunotherapy efficacy in BRAF mutation non-small-cell lung cancer. Cell death & disease 13 (12) (2022)
Hui Li, Yong-Chang Zhang, Yanjun Xu, Zhiyu Huang, Guoping Cheng, Ming-Ying Xie, Zi-Chao Zhou, Yangyang Yu, Wenjing Xi, Yun Fan
Tumor immune microenvironment and immunotherapy efficacy in BRAF mutation non-small-cell lung cancer. Cell death & disease 13 (12) (2022)
Hui Li, Yong-Chang Zhang, Yanjun Xu, Zhiyu Huang, Guoping Cheng, Ming-Ying Xie, Zi-Chao Zhou, Yangyang Yu, Wenjing Xi, Yun Fan
Tumor immune microenvironment and immunotherapy efficacy in BRAF mutation non-small-cell lung cancer. Cell death & disease 13 (12) (2022)